Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.12 (
PKG
)
2,515
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Vascular lesions
resulting from injury are characterized by a thickening of the intima brought about in part through the production of increased amounts of extracellular matrix proteins by the vascular smooth muscle cells (VSMCs). In this study, we tested the hypothesis that
cGMP-dependent protein kinase
(
PKG
), an important mediator of NO and cGMP signaling in VSMCs, inhibits the production of two extracellular matrix proteins, osteopontin and thrombospondin, which are involved in the formation of the neointima. VSMCs deficient in
PKG
were stably transfected with cDNAs encoding either the holoenzyme
PKG
-Ialpha or the constitutively active catalytic domain of
PKG
-I in order to directly examine the effects of
PKG
on osteopontin and thrombospondin production. Cells expressing either of the
PKG
constructs had dramatically reduced levels of osteopontin and thrombospondin-1 protein compared with control-transfected
PKG
-deficient cells.
PKG
transfection also altered the morphology of the VSMCs. These results indicate that
PKG
may be involved in suppressing extracellular matrix protein expression, which is one important characteristic of synthetic secretory VSMCs. Suppression of these matrix proteins may underlie the effects of NO-cGMP signaling to inhibit VSMC migration and phenotypic modulation.
...
PMID:Cyclic GMP-dependent protein kinase inhibits osteopontin and thrombospondin production in rat aortic smooth muscle cells. 946 84